MXD3 has been shown to predict poor prognosis in clear cell renal cell carcinoma (Zhang et al., 2021) and hepatocellular carcinoma (Xu et al., 2019), as well as having been indicated as a new molecular targeted site to treat neuroblastoma (Yoshida et al., 2020). Here, MXD3 is linked to hepatocellular carcinoma.